期刊文献+

海洋抗癌活性物质最新研究概况 被引量:8

Overview of Recent Progress on Marine Anticancer Active Substances
下载PDF
导出
摘要 分类简要概述近年来源自海洋生物抗肿瘤药物的最新研究与开发,其中包括肽类、大环内酯类、生物碱类、萜类、多聚乙酰类、多烯醚类等。海洋抗癌活性物质在海洋天然产物研究中占据重要地位,大多具有新结构和新作用机制,其中许多化合物作为抗癌药物已进入临床前及临床研究阶段。 The recent research and development of marine anticancer active substances were briefly summarized in classified manner, including peptides, macrolides, alkaloids, terpenes, polyketide, polyene ethers and so on. The marine anticancer active substances play important roles in the research of natural products from marine sources, which are mostly characterized by new structures and new mechanisms of action, and some of them as anticancer agents have entered preclinical or clinical trials.
出处 《药学进展》 CAS 2005年第7期302-309,共8页 Progress in Pharmaceutical Sciences
关键词 海洋抗肿瘤药物 细胞调亡 细胞毒性 作用机制 Marine anticancer agent Cell apoptosis Cytotoxicity Mechanism of action
  • 相关文献

参考文献26

  • 1Hoffman M A, Blessing J A, Lentz S S, et al. A phase Ⅱ trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study[ J]. Gynecol Oncol, 2003, 89(1) :95-98.
  • 2Hashiguchi N, Kubota T, Koh J, et al. TZT-1027, elucidates antitumors activity through direct cytotoxicity and selective blockade of blood supply [ J ]. Anticancer Res,2004, 24(4):2201-2208.
  • 3Schoffski P, Thate B, Beutel G, et al. Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer[ J].Ann Oncol, 2004, 15(4) :671-679.
  • 4Brandon E F, Sparidans R W, Meijerman I, et al. In vitro characterization of the biotransformation of thiocoraline, a novel marine anti-cancer drug[J]. Invest New Drugs, 2004,22(3): 241-251.
  • 5Terracciano S, Bruno I, Bifulco G, et al. Synthesis, conformational analysis, and cytotoxicity of new analogues of the natural cyclodepsipeptide jaspamide[J]. J Nat Prod, 2004,67(8) :1325-1331.
  • 6Chevallier C, Richardson A D, Edler M C, et al. A new cytotoxic and tubulin-interactive milnamide derivative from a marine sponge Cymbastela sp[J]. Org Lett, 2003, 5(20):3737-3739.
  • 7Ciruelos C, Trigo T, Pardo J, et al. A phase I clinical and pharmacokinetic (PK) study with Kahalahde F (KF) in patients (pts) with advanced solid tumours (AST) with a continuous weekly (W) 1-hour iv infusion schedule[ J]. Eur J Cancer, 2002, 38(Suppl 7): S33.
  • 8Marco E, Martin-Santamaria S, Cuevas C, et al. Structural basis for the binding of didemnins to human elongation factor eEF1A and rationale for the potent antitumor activity of these marine natural products[J]. J Med Chem, 2004, 47( 18):4439-4452.
  • 9Ding X B, Vera M D, Liang B, et al. Structure-activity relationships of side-chain modified didemnins[J]. Bioorg Med Chem Lett, 2001, 11(2) :231-234.
  • 10Cuadrado A, Gonzalezl L, Suarez Y, et al. JNK activation is critical for Aplidin-induced apoptosis [ J ]. Oncogene, 2004,23 (27): 4673-4680.

同被引文献133

引证文献8

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部